Schering Caught In WHI Wake
Executive Summary
Disturbing news from a major hormone study, bad regulatory luck, and a botched attempt to reassure German gynecologists have hurt Schering's HRT business. Yet the company hopes to use its risk-lowering franchise strategy to distinguish its HRT products from competitors'.
You may also be interested in...
Schering: Addressing the Specialist Challenge
As a large yet specialist firm, Schering must compete in multiple areas. That means developing and marketing differentiated products across a number of fronts--and dealing with the lower-than-average margins that typically come with mixed portfolios. How well the German group overcomes these challenges should be of growing interest to Big Pharma, given the risks of relying on blockbusters.
Galen's Generic Gamble
Galen's $359 million acquisition of Pfizer's women's health portfolio fits in well with the group's strategy to date. But the structure of the deal also highlights Galen's increasing exposure to generic competition.
Akzo Pharma's Fall and Rise
The recent meltdown at Akzo Nobel's Pharma unit was caused by a perfect storm of genericization, macroeconomic gloom, pipeline delays and product underperformance. But Akzo Pharma hopes that by beefing up R&D and cutting costs through restructuring, it can return to growth in 2005.